Abstract
P094 A Phase II study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 in patients with cystic fibrosis bronchiectasis (the Clairafly™ study)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have